ArticleBiomaterials research2025
Development of Natural Killer Cell-Drug Conjugates via Membrane-Installed Liposomes for Pancreatic Cancer Treatment.
Article in Biomaterials research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adoptive cell-based therapy has emerged as an innovative method for cancer treatment, capitalizing on the innate cytotoxicity of immune cells to eliminate tumors. Although chimeric-antigen-receptor-modified T and natural killer (NK) cells have demonstrated significant therapeutic potential, their clinical translation is hindered by the complex nature of genetic engineering, high production costs, and risks of severe immune-related adverse effects. Addressing these barriers, we present a biomaterial-based approach to engineering NK cells, entirely bypassing the need for genetic modification. Initially, we systematically evaluated the surface modification of NK cells by employing a range of dibenzocyclooctyne (DBCO)-lipid biomaterials based on 1,2-distearoyl-
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.